SRR1383018
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.542
- INTERFERON_ALPHA_RESPONSE+0.487
- INFLAMMATORY_RESPONSE+0.475
- INTERFERON_GAMMA_RESPONSE+0.456
- IL6_JAK_STAT3_SIGNALING+0.449
- IL2_STAT5_SIGNALING+0.405
- COAGULATION+0.349
- ALLOGRAFT_REJECTION+0.342
- APOPTOSIS+0.328
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.325
Top 10 suppressed
- G2M_CHECKPOINT-0.400
- E2F_TARGETS-0.396
- NOTCH_SIGNALING-0.379
- MITOTIC_SPINDLE-0.375
- DNA_REPAIR-0.331
- OXIDATIVE_PHOSPHORYLATION-0.263
- UV_RESPONSE_DN-0.190
- PROTEIN_SECRETION-0.160
- WNT_BETA_CATENIN_SIGNALING-0.159
- MYC_TARGETS_V1-0.139
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
3 twins match this tumor's tissue · 7 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2598312 | fetal | fetal | 0.937 |
| 2 | SJEPD037_R.RNA-Seq | EPN | Posterior Fossa EPN | 0.937 |
| 3 | SJEPD038_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.915 |
| 4 | ERR2598287 | fetal | fetal | 0.905 |
| 5 | SJEPD001506_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.904 |
| 6 | SRR608662 | GTEX | — | 0.900 |
| 7 | SRR1316254 | GTEX | — | 0.900 |
| 8 | BS_769BDPDB | pilocytic astrocytoma | — | 0.898 |
| 9 | s_150203_1a | EPN | Posterior Fossa EPN | 0.894 |
| 10 | SRR1440356 | GTEX | — | 0.893 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.542 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.487 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.475 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.456 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.449 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.405 | Idelalisib | — uncovered |
| COAGULATION | 0.349 | Binimetinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.342 | Idelalisib | — uncovered |
| APOPTOSIS | 0.328 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.325 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.312 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.299 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.298 | Idelalisib | — uncovered |
| HYPOXIA | 0.277 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.277 | Idelalisib | — uncovered |
| MYOGENESIS | 0.274 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.255 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.235 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.227 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.218 | Inavolisib | — uncovered |